Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) may contribute to the pathogenesis of atherosclerosis
Authors:
- 11 September 2023
- journal article
- research article
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 169, 106781
Abstract
No abstract availableKeywords
Funding Information
- Kermanshah University of Medical Sciences Vice Chancellor for Research and Technology (97062)
- Kermanshah University of Medical Sciences
This publication has 33 references indexed in Scilit:
- Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRsProgress in Lipid Research, 2012
- Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1PLOS ONE, 2011
- Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral AtherosclerosisThe American Journal of Pathology, 2010
- Resolvins and protectins: Natural pharmacophores for resolution biologyProstaglandins, Leukotrienes and Essential Fatty Acids, 2010
- Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1Prostaglandins & Other Lipid Mediators, 2009
- Leukotriene B4 enhances the activity of nuclear factor- B pathway through BLT1 and BLT2 receptors in atherosclerosisCardiovascular Research, 2008
- The immune response in atherosclerosis: a double-edged swordNature Reviews Immunology, 2006
- Resolution of inflammation: the beginning programs the endNature Immunology, 2005
- Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airwayNature Immunology, 2004
- Inflammation and AtherosclerosisCirculation, 2002